Exclusive Summary

• - Originator Takeda (Nesina); core patent/SPC have largely expired between 2020–2025, with generics already present in the US/EU/Japan.
• - Over 500 million adults live with T2D globally, sustaining large oral therapy demand; DPP-4s retain meaningful share in Asia and in elderly/renal impairment segments.
• - Alogliptin offers moderate A1C reduction, weight neutrality, low hypoglycemia, and CV safety, fitting patients who cannot use SGLT2/GLP-1 or prefer simple oral regimens.
• - Competition is broad (10+ US ANDAs and multiple EU/JP MAHs), yet portfolio-gap opportunities remain where SGLT2/GLP-1 dominate and cost is critical.
• - Generic pricing typically achieves >70–90% discount vs brands, supporting tender wins and cash-pay affordability.